International Journal of Toxicology; December 2017 | Nonclinical Development of ANX005: A Humanized Anti-C1q Antibody for Treatment of Autoimmune and Neurodegenerative Diseases | Janice A. Lansita, et al.

STAT; August 2017 | ‘Beyond amyloid’: A look at what’s next in Alzheimer’s research? | Damian Garde


Blood; 2016ANX005, an Inhibitory Antibody Against C1q, Blocks Complement Activation Triggered By Cold Agglutinins in Human Disease | Morie A. Gertz, et al.

Science; August 2016This woman may know a secret to saving the brain’s synapses | Emily Underwood

Cell Development; July 2016Microglia: Phagocytosing to Clear, Sculpt, and Eliminate | Soyon Hong & Beth Stevens

Cell; May 2016 | Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation | Hansen Lui, et al.

Nature Reviews; April 2016 | Complement mediates pathological pruning | Katherine Whalley

Science; April 2016 | Complement and microglia mediate early synapse loss in Alzheimer mouse models | Soyon Hong, et al.

Molecular Neurodegeneration; April 2016 | Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma | Pete A. Williams, et al.

Molecular Neurodegeneration; March 2016 | C1q propagates microglial activation and neurodegeneration in the visual axis following retinal ischemia/reperfusion injury | Sean M. Silverman, et al.

Acta Neuropathologica Communications; March 2016 | C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy | Rhona McGonigal, et al.

Nature; February 2016 | Schizophrenia risk from complex variation of complement component 4 | Aswin Sekar, et al.


Scientific American; October 2015 | Rise of the Microglia: New research shows that the resident immune cells of the brain are involved in both development and disease | Diana Kwon

Nature Reviews Drug Discovery; October 2015 | Complement, a target for therapy in inflammatory and degenerative diseases | B. Paul Morgan & Claire L. Harris


J of Neuroscience; August 2013 | A Dramatic Increase of C1q Protein in the CNS during Normal Aging | Alexander H. Stephan, et al.

Acta Neuropathologica; June 2013 | C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica | Puay-Wah Phuan, et al.


Science; August 2012 | The New View of Complement | Mitch Leslie

Annual Review of Neuroscience; July 2012 | The Complement System: An Unexpected Role in Synaptic Pruning During Development and Disease | Alexander H. Stephan, et al.

Neuron; May 2012 | Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner | Dorothy P. Schafer, et al.


J Clinical Investigation; April 2011 | Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma | Gareth R. Howell, et al.


Advances in Experimental Medicine and Biology; July 2010 | The Role of the Classical Complement Cascade in Synapse Loss During Development and Glaucoma | Allison M. Rosen & Beth Stevens


Cell; December 2007 | The Classical Complement Cascade Mediates CNS Synapse Elimination | Beth Stevens, et al.


2017 AAN Annual Meeting: Characterization and development of ANX005, a novel function blocking anti-C1q antibody for treatment of autoimmune and neurodegenerative disease | Sethu Sankaranarayanan, et al. 2017. (pdf)

2016 ASH Annual MeetingANX005, an Inhibitory Antibody Against C1q, Blocks Complement Activation Triggered By Cold Agglutinins in Human Disease | Morie Gertz, et al 2016. (pdf)

2016 Keystone Conference: Characterization of a function blocking anti-C1q antibody and its evaluation in neurodegenerative disease models. Sethu Sankaranarayanan, et al. 2016. (pdf)